Literature DB >> 35139223

"An Extra Variable to Consider"-Vaccine-Induced Seropositivity and Adolescent HIV Vaccine Clinical Trials.

Omolayo Fatola1, Amy Corneli2,3, Brian Perry2, Emily Hanlen-Rosado2, Adora Nsonwu2, Evangelia P Constantine4, Amelia B Thompson5,6,7.   

Abstract

Our study explores the understanding of vaccine-induced seropositivity (VISP) and its potential impact on US adolescents' and caregivers' willingness to participate in adolescent HIV vaccine clinical trials. Findings from in-depth interviews suggest that addressing concerns about VISP will be essential for future pediatric HIV vaccine trials in the United States.
© The Author(s) 2022. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV; VISP; adolescent; prevention; vaccine

Mesh：

Substances：

Year:  2022        PMID： 35139223      PMCID： PMC9155599          DOI： 10.1093/jpids/piac001

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN： 2048-7193            Impact factor:   5.235


  9 in total

1.  Inclusion of Adolescents in STI/HIV Biomedical Prevention Trials: Autonomy, Decision Making, and Parental Involvement.

Authors:  Susan L Rosenthal; Marilyn C Morris; Lily F Hoffman; Gregory D Zimet
Journal:  Clin Pract Pediatr Psychol       Date:  2018-05-24

2.  Adolescent decision making about participation in a hypothetical HIV vaccine trial.

Authors:  Andreia B Alexander; Mary A Ott; Michelle A Lally; Kevin Sniecinski; Alyne Baker; Gregory D Zimet
Journal:  Vaccine       Date:  2015-01-30       Impact factor: 3.641

3.  Evaluation of a video-supplement to informed consent: injection drug users and preventive HIV vaccine efficacy trials.

Authors:  I Fureman; K Meyers; A T McLellan; D Metzger; G Woody
Journal:  AIDS Educ Prev       Date:  1997-08

Review 4.  Progress in HIV vaccine development.

Authors:  Denise C Hsu; Robert J O'Connell
Journal:  Hum Vaccin Immunother       Date:  2017-03-10       Impact factor: 3.452

5.  Being "False Positive": An "Inconvenience"? Debates and Questions Regarding the Notion of Vaccine-Induced Seropositivity (VISP) in the Recruitment of Healthy Volunteers for a Preventive Anti-HIV Vaccine Trial.

Authors:  Mathilde Couderc
Journal:  J Acquir Immune Defic Syndr       Date:  2018-10-01       Impact factor: 3.731

6.  Long-term safety and vaccine-induced seropositivity in healthy volunteers from HIV vaccine trials.

Authors:  Christine Durier; Corinne Desaint; Jean-Daniel Lelièvre; Benjamin Silbermann; Gilles Pialoux; Lise Cuzin; Bénédicte Bonnet; Isabelle Poizot-Martin; Amel Bouakane; Christelle Paul; Sophie Grabar; Bruno Spire; Laurence Meyer; Odile Launay
Journal:  AIDS       Date:  2019-11-01       Impact factor: 4.177

7.  Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.

Authors:  Cristine J Cooper; Barbara Metch; Joan Dragavon; Robert W Coombs; Lindsey R Baden
Journal:  JAMA       Date:  2010-07-21       Impact factor: 56.272

Review 8.  HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians.

Authors:  Yegor Voronin; Helene Zinszner; Carissa Karg; Katie Brooks; Robert Coombs; John Hural; Renee Holt; Pat Fast; Mary Allen
Journal:  Vaccine       Date:  2015-01-31       Impact factor: 3.641

9.  Preventing HIV among adolescents with oral PrEP: observations and challenges in the United States and South Africa.

Authors:  Sybil Hosek; Connie Celum; Craig M Wilson; Bill Kapogiannis; Sinead Delany-Moretlwe; Linda-Gail Bekker
Journal:  J Int AIDS Soc       Date:  2016-10-18       Impact factor: 5.396
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.